The Clinical Relevance of Rising CA-125 Levels Within the Normal Range in Patients With Uterine Papillary Serous Cancer

Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma

(2011) Divya Gupta et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

(2010) Gordon JS Rustin et al.   LANCET

Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review

(2009) David M. Boruta et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

(2009) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY

Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths

(2008) Stefanie M. Ueda et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

(2008) A. Prat et al.   ANNALS OF ONCOLOGY

Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma

(2008) Alexander B. Olawaiye et al.   GYNECOLOGIC ONCOLOGY

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer

(2007) A. Prat et al.   ANNALS OF ONCOLOGY